We are pleased to share that Argus Partners advised MedGenome Inc. (“MedGenome”), a leading, genomic diagnostics and research services company, on its Series E fundraise of approximately USD 47.5 million. The round was co-led by Maj Invest, along-with existing investor Novo Holdings and saw participation from Sofina Ventures, also an existing investor in MedGenome.

The fundraise will enable MedGenome to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets. The funding will further strengthen MedGenome’s efforts to reduce India’s disease burden through early detection and targeted disease management using affordable, genetics-based diagnostic tools.

Speaking about how this funding aligns with the company’s vision, Dr. Vedam Ramprasad, CEO of MedGenome, said, “India's healthcare ecosystem is increasingly recognizing the transformative potential of genomics, driving innovation and enhancing the country’s healthcare capabilities. This fundraise also reflects the growing adoption of genomics in personalized and preventive healthcare in India as well as other emerging economies. At MedGenome, we combine cutting-edge science with real-world application, bringing advanced omics solutions that bridge the unmet need in disease diagnosis and management. Early genomics-led intervention not only helps the patient but also helps families manage the economic and emotional burden of a disease."

Dr. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, commented, “our reinvestment in MedGenome reflects our belief in the company’s potential to transform the landscape of genetic and integrated diagnostics in India and beyond. MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets. We are pleased to continue our support for the company as it expands access to genomic healthcare solutions and advances its mission to make a meaningful impact on health outcomes globally."

Jannick Dam Mortensen, Partner, Maj Invest Minorities, added, "With its robust genomics portfolio, commitment to science and the transformative impact it has had on healthcare, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We’re proud to support their next phase of growth, expanding their solutions to more markets in India and worldwide".

The team at Argus Partners advising MedGenome consisted of Abhinav Bhalaik, Armaan Patkar (Partners), Ishita Agarwal (Senior Associate) and Anoushka Goel (Associate).